<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic immunotherapy for myasthenia gravis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic immunotherapy for myasthenia gravis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic immunotherapy for myasthenia gravis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shawn J Bird, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness involving ocular, bulbar, limb, and/or respiratory muscles. The weakness is due to an antibody-mediated, immunologic attack directed at proteins in the postsynaptic membrane of the neuromuscular junction (acetylcholine receptors or receptor-associated proteins). MG is the most common disorder of neuromuscular transmission.</p><p>MG can be managed effectively with therapies that include anticholinesterase agents, immunosuppressive and immunomodulatory therapies, and thymectomy. While anticholinesterase agents and intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) are effective for rapid and short-term control of symptoms, most patients with MG require chronic immunotherapy at some point in their illness, if not indefinitely, to maintain disease stability.</p><p>The chronic immunosuppressive and immunomodulatory therapies used in the treatment of MG will be reviewed here. The general approach to the treatment of MG and to common clinical situations in patients with MG is discussed separately. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a> and  <a class="medical medical_review" href="/d/html/5125.html" rel="external">"Myasthenic crisis"</a>.)</p><p>Other aspects of myasthenia gravis are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5153.html" rel="external">"Pathogenesis of myasthenia gravis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5170.html" rel="external">"Clinical manifestations of myasthenia gravis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5130.html" rel="external">"Diagnosis of myasthenia gravis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5168.html" rel="external">"Differential diagnosis of myasthenia gravis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5132.html" rel="external">"Management of myasthenia gravis in pregnancy"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">GLUCOCORTICOIDS</span></p><p class="headingAnchor" id="H1915420054"><span class="h2">Indications and rationale</span><span class="headingEndMark"> — </span>Immunotherapy is usually required for patients who remain significantly symptomatic on anticholinesterase therapy (<a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a>), or who become symptomatic again after a temporary response to pyridostigmine. Due to their rapid onset of effect, glucocorticoids are the most commonly used initial immunosuppressive therapy in this setting  (<a class="graphic graphic_table graphicRef70721" href="/d/graphic/70721.html" rel="external">table 1</a>).</p><p>Observational studies and clinical experience support the efficacy of glucocorticoids in the treatment of MG [<a href="#rid1">1</a>]. Limited evidence from randomized, controlled trials likewise suggests that glucocorticoid treatment offers significant short-term benefit in MG compared with placebo [<a href="#rid2">2</a>]. The administration of moderate or high (1 mg/kg per day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) doses of glucocorticoids produces remission in approximately 30 percent of patients and marked improvement in another 50 percent [<a href="#rid3">3,4</a>]. The onset of benefit generally begins within two to three weeks and peaks after a mean of 5.5 months.</p><p>There are several options for patients who are at increased risk for glucocorticoid complications in order to minimize the duration of the initial <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> course or to avoid glucocorticoids completely, including early introduction of a nonsteroidal immunosuppressive therapy (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) and bridge therapy with antibody-based biologics, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), or therapeutic plasma exchange. The strategy should be individualized depending on the severity of disease and the nature of the comorbid risk factor. (See <a class="local">'Glucocorticoid-sparing therapy'</a> below and <a class="local">'Weaning from glucocorticosteroids'</a> below.)</p><p class="headingAnchor" id="H2623179756"><span class="h2">Risk of transient worsening</span><span class="headingEndMark"> — </span>When high-dose glucocorticoids are started, up to 50 percent of patients develop a transient deterioration that can be serious [<a href="#rid4">4,5</a>], and up to 10 percent have respiratory failure requiring mechanical ventilation. The transient worsening usually occurs 5 to 10 days after the initiation of glucocorticoids and lasts approximately five or six days.</p><p>For this reason, glucocorticoids are most often started in high doses only in hospitalized patients who are receiving concurrent plasma exchange or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> for myasthenic crisis. Plasma exchange and IVIG have a quick onset of action that precludes the transient worsening of MG that would otherwise occur due to the glucocorticoids. (See  <a class="medical medical_review" href="/d/html/5125.html" rel="external">"Myasthenic crisis", section on 'Rapid therapies'</a>.)</p><p>In the outpatient setting, a gradual dose escalation of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is advised to reduce the risk of transient worsening. (See <a class="local">'Initial dose escalation'</a> below.)</p><p class="headingAnchor" id="H1293939768"><span class="h2">Administration of prednisone</span></p><p class="headingAnchor" id="H4"><span class="h3">Initial dose escalation</span><span class="headingEndMark"> — </span>To avoid the transient worsening that can occur early after starting high-dose glucocorticoids, an outpatient dose escalation regimen works quite effectively [<a href="#rid6">6</a>]. This is the preferred strategy for patients who do not have rapidly progressive symptoms, or those who do not have significant bulbar or respiratory symptoms. Patient with more severe exacerbations should be treated with plasma exchange or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> before starting glucocorticoids. (See  <a class="medical medical_review" href="/d/html/5125.html" rel="external">"Myasthenic crisis", section on 'Rapid therapies'</a>.)</p><p>We typically start <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at 20 mg daily and then increase by 5 mg every three to five days to a usual target dose of 60 mg per day (or 1 mg/kg per day, maximum 80 mg daily). This often takes four to eight weeks. By that time, it is generally clear if there is a response to glucocorticoids. Tapering of the dose can then begin after a month or so at this dose.</p><p>The maximum daily dose can also be individualized. If the patient has responded completely with resolution of the symptoms at a lower dose, then the dose does not need to go any higher. However, it is probably wise to hold the dose at that level for a month or so to be certain that the response is sustained, before beginning a tapering schedule.</p><p class="headingAnchor" id="H3719532624"><span class="h3">Approach to tapering</span><span class="headingEndMark"> — </span>Once an effective response is obtained, it is important not to taper the glucocorticoids too quickly, or else relapse is likely. Also, it should be remembered that worsening due to a reduction in dose typically takes at least two weeks.</p><p>Glucocorticoid tapering can be done with the final goal of achieving either a daily or alternate-day regimen. We use daily dosing of glucocorticoids in MG. However, there are no data to support the benefits of one over the other in myasthenia. Which of these regimens to choose is determined by the individual nature of the patient's medical health and the myasthenia. Daily dosing may be preferred for younger patients, those with little in the way of side effects, and patients with diabetes (to get a more even daily effect on blood sugars).</p><p>With either regimen, the daily dose may be reduced by 5 to 10 mg each month until below 30 mg, then more slowly thereafter (eg, 5 mg per month or slower). As an example, with the every-other-day regimen, the taper from 80 mg daily would begin with 80 mg alternating with 60 mg, then a month later to 80 mg alternating with 40 mg, and eventually to 80 mg alternating with 0 mg. Tapering of the high-dose day would then commence. It may be necessary to go back up to a higher dose by at least 10 to 20 mg if symptoms recur during the taper.</p><p>Many patients who respond to glucocorticoids can be effectively tapered down to approximately 10 mg per day (or 20 mg every other day) as a maintenance dose that keeps them minimally symptomatic. Young patients, in particular, tolerate such doses well with few of the side effects of these drugs. To avoid relapse, patients may need to stay on this maintenance dose for years, if not indefinitely. The relapse rate is not well defined.</p><p>Other immunotherapies are often needed in combination with glucocorticoids, either because of insufficient response, inability to taper glucocorticoids without recurrent symptoms, or development of toxicities of chronic steroid use. (See <a class="local">'Glucocorticoid-sparing therapy'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h3">Side effects and monitoring</span><span class="headingEndMark"> — </span>The major disadvantages with chronic glucocorticoid use are their well-recognized side effects. Most are not specific to myasthenia and are dose and duration of treatment dependent. These commonly include weight gain, Cushingoid facies, easy bruising and skin fragility, cataracts, aseptic necrosis of the femoral or humeral heads, hypertension, diabetes, and osteoporosis. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Patients should be advised of the potential weight gain and provided an appropriate diet if necessary. Calcium (1500 mg per day) and vitamin D (400 to 800 international units per day) supplementation should be used to reduce bone mineral loss, especially postmenopausal patients. For those most at risk for osteoporosis, bone density should be measured at the start of treatment and then periodically. If bone mineral loss has occurred, patients are generally given a bisphosphonate or an alternative agent. (See  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p>A histamine-2 blocker does not need to be used routinely, but it should be given in patients with a history of peptic ulcer disease or those who develop symptoms of gastritis. Blood pressure and serum glucose levels should be routinely monitored. Yearly checks for cataracts and glaucoma are also recommended.</p><p><em>Pneumocystis</em> pneumonia prophylaxis should be considered for patients who are treated with significant doses of glucocorticoids (eg, ≥20 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> daily for one month or longer) in combination with a second immunosuppressive drug. (See  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">GLUCOCORTICOID-SPARING THERAPY</span><span class="headingEndMark"> — </span>Nonsteroidal immunotherapy plays an important role in the management of MG for patients with an insufficient response to glucocorticoids, for those who cannot taper glucocorticoids below a reasonably acceptable level without return of symptoms, and as a steroid-sparing therapy in patients with toxicities of chronic glucocorticoid use.</p><p class="headingAnchor" id="H1225642198"><span class="h2">Selection of therapy</span></p><p class="headingAnchor" id="H3555944986"><span class="h3">AChR-positive and seronegative MG</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are the most commonly used glucocorticoid-sparing therapies in patients with acetylcholine receptor (AChR) antibody positive or seronegative MG. Alternative agents include <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="134678" href="/d/drug information/134678.html" rel="external">efgartigimod alfa</a>, <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, and <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is used infrequently.</p><p>None of these agents have been compared head to head in patients with MG, and they have variable side effect profiles, cost, availability, and time to maximal effect  (<a class="graphic graphic_table graphicRef70721" href="/d/graphic/70721.html" rel="external">table 1</a>).</p><p>Absent data from comparative trials, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> is supported as a first-line glucocorticoid-sparing agent by expert consensus, observational data, and limited randomized trial evidence [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil is equally reasonable and is widely used first line in many centers, although randomized trial evidence does not yet support its effectiveness. Each of the antibody-based biologic therapies may be used as a glucocorticoid-sparing therapy with a more rapid onset of effect than other available agents. <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> have activity in MG and may achieve results faster than azathioprine or mycophenolate, but concerns about kidney toxicity and drug interactions limit their use as first-line steroid-sparing agents. In rare patients with contraindications to both drugs (eg, active liver disease for azathioprine and lymphopenia for either azathioprine or mycophenolate), cyclosporine or tacrolimus may be used as an initial oral glucocorticoid-sparing agent. (See <a class="local">'Administration of specific drugs'</a> below.)</p><p class="headingAnchor" id="H3294628719"><span class="h3">MuSK-positive MG</span><span class="headingEndMark"> — </span>International expert consensus guidelines emphasize growing clinical evidence that muscle-specific tyrosine kinase (MuSK)-positive MG has important differences with regard to treatment compared with AChR antibody-positive and seronegative MG [<a href="#rid1">1</a>]. Most patients with MuSK-positive disease are poorly responsive to anticholinesterase agents. While many patients respond to glucocorticoids, they are more likely to remain steroid dependent despite the addition of other immunotherapeutic agents such as <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil.</p><p><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> has emerged as a preferred early therapy in these patients, especially if there is an unsatisfactory response to initial glucocorticoids, based on accumulating referral center experience and observational data suggesting that MuSK-positive patients may respond particularly well to rituximab. If cost or access to rituximab is prohibitive, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil remain reasonable to use as first-line steroid-sparing therapies [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">Rozanolixizumab</a> was approved by the United States Food and Drug Administration (FDA) in 2023, including for patients with MuSK-positive MG, but its place in MG treatment has not yet been defined. (See <a class="local">'Rituximab'</a> below and <a class="local">'Azathioprine'</a> below and <a class="local">'Mycophenolate'</a> below and <a class="local">'Rozanolixizumab'</a> below.)</p><p class="headingAnchor" id="H4184758681"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">Pyridostigmine</a> is a first-line therapy for MG during pregnancy, and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is the immunotherapy of choice in patients who are not adequately controlled by symptomatic therapy alone.</p><p>In patients who cannot be adequately controlled on <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, selective use of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> during pregnancy is warranted when the benefits of immunosuppression with this agent appear to outweigh the risks. There is a consensus that azathioprine is safer in pregnancy than other immunosuppressant drugs, including <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Azathioprine and 6-mercaptopurine'</a>.)</p><p>As with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, selective use of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> during pregnancy is warranted when the benefits of immunosuppression with these drugs appear to outweigh the risks. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclosporine'</a> and  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tacrolimus'</a>.)</p><p><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> carries a moderate to high risk of fetal harm. Thus, its use for patients who may become pregnant should be reserved for those with severe disease who use reliable means of contraception. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Mycophenolate mofetil'</a>.)</p><p>Prepregnancy planning and management of MG during pregnancy and the postpartum period are reviewed separately. (See  <a class="medical medical_review" href="/d/html/5132.html" rel="external">"Management of myasthenia gravis in pregnancy"</a>.)</p><p class="headingAnchor" id="H3574522257"><span class="h3">Older adults</span><span class="headingEndMark"> — </span>We use glucocorticoids in older individuals who need a relatively quick response to immunotherapy and then try to add another agent (most often <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) to replace the glucocorticoids for the long term.</p><p>Other than a tendency to use glucocorticoids more sparingly in this group, the use of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> does not differ from younger patients. Due to the potential kidney side effects, we do not commonly use <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> in these patients. (See <a class="local">'AChR-positive and seronegative MG'</a> above.)</p><p>There are few studies that look at the treatments in this particular age group. However, the usefulness of immunotherapy is supported by a study of outcome at one year or longer in 149 patients with disease onset after age 60 who were treated with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> with or without <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid8">8</a>]. Better outcomes and fewer side effects were observed when prednisone was avoided or was combined with azathioprine.</p><p class="headingAnchor" id="H8"><span class="h2">Administration of specific drugs</span></p><p class="headingAnchor" id="H691734868"><span class="h3">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> is a purine analogue that inhibits the synthesis of nucleic acids. It interferes with T and B cell proliferation and lowers AChR antibodies in patients with MG.</p><p>The goal of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> in most cases is to maintain disease control while avoiding the long-term consequences of glucocorticoid treatment. The more rapidly acting glucocorticoid (<a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) is usually started first for short-term effect, and then azathioprine is initiated once prednisone has been tapered to a stable, relatively low dose. The ultimate goal is to slowly withdraw the steroids entirely. However, this can take longer than a year to achieve.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment screening</strong> – Before starting <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, it is prudent to screen patients for variants in the thiopurine methyltransferase (<em>TPMT</em>) gene that causes TPMT deficiency. One in 300 individuals is homozygous for a genetic variant and has very low or absent enzyme levels. Such patients should not receive azathioprine because they cannot metabolize the drug and may develop life-threatening bone marrow suppression. Patients who are heterozygous for a genetic variant generally have low enzyme activity but can tolerate azathioprine at lower than usual doses. Specific dosing recommendations for thiopurines according to <em>TPMT</em> genotype are available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcpicpgx.org%2F&amp;token=zjLVfmxyYF0zItjS0b9hzXEA9ap4v06K9alZaoyhbSE%3D&amp;TOPIC_ID=5175" target="_blank">Clinical Pharmacogenetics Implementation Consortium</a> [<a href="#rid9">9</a>]. The guidelines are updated and available online at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.pharmgkb.org%2F&amp;token=xXI%2By9QNEPjV52%2B%2BDeHAeRSknjwZrSAAa8IM1A9AZ18sVzNz1i2SXggwyErj6gsH&amp;TOPIC_ID=5175" target="_blank">PharmGKB</a>. (See  <a class="medical medical_review" href="/d/html/2904.html" rel="external">"Overview of pharmacogenomics", section on 'Thiopurines and polymorphisms in TPMT and NUDT15'</a>.)</p><p></p><p class="bulletIndent1">Either commercially available genotype and/or phenotype (enzyme levels) testing for TPMT deficiency may be done. The TPMT erythrocyte enzyme level assay in serum is preferred because of lower cost and ready availability.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a>, whether used alone or in combination with glucocorticoids, is begun at a dose of 50 mg daily for two to four weeks. If it is tolerated without systemic side effects, it can be increased by 50 mg increments every two to four weeks to a maintenance dose of 2 to 3 mg/kg total body weight. In most patients, this is typically 150 to 200 mg each day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects and monitoring</strong> – Monthly monitoring of complete blood counts (CBCs) and liver function studies is warranted for the first six months and then less frequently if stable.</p><p></p><p class="bulletIndent1">The most common side effect encountered with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> is a flu-like illness with fever, nausea, vomiting, and malaise in 10 percent and then less frequent hematologic, gastrointestinal, or liver problems. The initial flu-like illness is idiosyncratic and develops within the first few weeks of treatment. The drug should be discontinued in the patient, and the symptoms quickly abate. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1">Hepatotoxicity, suppression of the white blood count, and pancreatitis are less common but serious potential adverse effects. For these reasons, it is useful to monitor with a CBC and liver function tests monthly for at least six months. The <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> dose should be decreased and the CBC monitored more frequently if the white blood count falls below 4000 cells/mm<sup>3</sup>. Azathioprine should be discontinued if the white blood cell count falls below 3000 cells/mm<sup>3</sup>. Azathioprine should also be discontinued if the liver function studies are more than mildly abnormal or continue to rise. Serum amylase should be performed if symptoms develop that are consistent with pancreatitis, and azathioprine should be discontinued if the amylase is elevated in this setting.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> causes a macrocytosis that increases the mean corpuscular volume (MCV). This is of little concern, but it can be used as a means to assess dosing and compliance [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1">Although it is quite uncommon in patients with MG, the risk of malignancy with long-term <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> use may be increased for non-Hodgkin lymphomas [<a href="#rid11">11</a>] and nonmelanotic skin cancer. The malignancy risk is likely relatively low and analogous to the experience seen with its use in rheumatoid arthritis. (See  <a class="medical medical_review" href="/d/html/7994.html" rel="external">"Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Malignancy risk'</a>.)</p><p></p><p class="bulletIndent1">There is an important drug interaction between <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and the xanthine oxidase inhibitors <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> and <a class="drug drug_general" data-topicid="9079" href="/d/drug information/9079.html" rel="external">febuxostat</a>. Xanthine oxidase inhibitors interfere with the metabolism of <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>, the active metabolite of azathioprine. Therefore, xanthine oxidase inhibitors should not be used in combination with azathioprine if possible.</p><p></p><p>In observational studies, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> improves MG symptoms in 70 to 90 percent of patients, but its major drawback is that the onset of any beneficial effect is delayed 6 to 12 months, with a maximal effect often not until one to two years of treatment [<a href="#rid12">12-15</a>]. This was demonstrated in a three-year randomized trial of <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> plus azathioprine versus prednisolone plus placebo in 34 patients with generalized MG [<a href="#rid16">16</a>]. At one year, the median prednisolone dose required to maintain remission was similar between groups (37.5 versus 45 mg prednisolone every other day for azathioprine and placebo groups, respectively). By three years, however, azathioprine lowered the median prednisolone dose (0 versus 40 mg every other day), the proportion of patients still requiring prednisolone (20 versus 63 percent), and the number of relapses and treatment failures. Confidence in these results is limited by patient attrition, in addition to the small sample size.</p><p class="headingAnchor" id="H10"><span class="h3">Mycophenolate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil blocks purine synthesis in lymphocytes and inhibits their proliferation. Like other steroid-sparing agents, it is typically started after patients achieve stability on low doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. It may have a slightly faster onset of effect compared with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The usual dose of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> is 2000 mg (1000 mg twice a day). After starting at 500 mg twice a day, the dose can be increased after one to four weeks to 1000 mg twice a day. Monthly CBCs are usually suggested for the first six months and periodically thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects and monitoring</strong> – Side effects are generally few with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>. The most common adverse side effects are gastrointestinal, mostly nausea or diarrhea. Leukopenia can occur, but rarely to the degree that warrants discontinuation of mycophenolate, particularly at doses (2000 mg daily or less) used in the treatment of MG. Nonetheless, monthly CBCs during the first six months of mycophenolate therapy, and then less frequently, are suggested. (See  <a class="medical medical_review" href="/d/html/7990.html" rel="external">"Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1">An unanswered question is the long-term safety of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>. There is no long-term experience with this agent in MG, as there is with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. In addition, it is hard to extrapolate mycophenolate risks from transplant recipients, where much higher mycophenolate doses and multiple other immunomodulating drugs are used. Most patients who develop lymphoid malignancies on mycophenolate are taking a combination of immunosuppressive agents; therefore, the risk attributable to mycophenolate as a single agent is uncertain. There are conflicting data regarding whether the risk of late malignancy, particularly lymphomas, is increased or not following therapy with mycophenolate [<a href="#rid17">17-20</a>].</p><p></p><p>Accumulated experience and expert opinion also support use of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil in MG, and it is widely used as a first-line agent in many centers [<a href="#rid1">1</a>]. Some feel that it has a slightly faster onset of effect compared with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> and is better tolerated on average. As with azathioprine, relatively short-term trials have failed to show a glucocorticoid-sparing effect within the first year of mycophenolate use compared with placebo [<a href="#rid21">21-23</a>]. In the largest trial, 172 patients with generalized MG taking <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> ≥20 mg daily for at least four weeks were randomly assigned to mycophenolate (2000 mg daily) or placebo [<a href="#rid21">21</a>]. At 36 weeks, there were no statistically significant differences in any outcomes, including a composite primary outcome (achievement of minimal disease symptoms or pharmacologic remission; 44 versus 39 percent for mycophenolate versus placebo), myasthenia symptoms, and median glucocorticoid dose.</p><p>Observational studies both before and after this trial have suggested a benefit of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> with longer-term follow-up, however [<a href="#rid24">24-27</a>]. One retrospective study from two centers included 102 patients with acetylcholine receptor (AChR) antibody-positive generalized disease who were treated with mycophenolate alone or mycophenolate and <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid24">24</a>]. Eighty percent of those followed for more than 24 months had a desirable outcome (minimal clinical manifestations or better), and the percentage of those who achieved this target began to rise as early as six months into treatment. The prednisone dose required began to fall after 12 months. After 24 months of mycophenolate treatment, 55 percent of the patients were able to come off prednisone entirely and 75 percent were on less than 7.5 mg daily.</p><p class="headingAnchor" id="H12"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> selectively inhibits calcineurin, impairs the production of interleukin-2, inhibits the function of T helper cells, and dampens T lymphocyte-dependent immune responses. Kidney toxicity, hypertension, and drug interactions limit its use as a first-line steroid-sparing agent, however.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – When used in patients with MG, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is typically started at 2.5 mg/kg per day in divided doses. The dose can be increased in 0.5 mg/kg per day increments every four to eight weeks as tolerated to a maximum of 5 mg/kg per day. Clinical practice varies with regard to monitoring of cyclosporine levels; some have suggested aiming for trough levels &lt;300 ng/mL.</p><p></p><p class="bulletIndent1">Clinical benefit in MG can often be appreciated as early as one to two months after starting <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects and monitoring</strong> – Hypertension and nephrotoxicity are the most common limiting adverse effects of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. Progressive nephrotoxicity occurs in up to 10 percent of patients. Serum creatinine and blood pressure must be monitored regularly, as well as serum trough cyclosporine levels. (See  <a class="medical medical_review" href="/d/html/7357.html" rel="external">"Cyclosporine and tacrolimus nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1">Other <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> side effects include tremor, nausea, gingival hyperplasia, myalgias and flu-like symptoms, and hypertrichosis. The risk of malignancy, primarily squamous cell skin cancer and lymphoma, may also be increased with long-term use [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1">Through its metabolism via the cytochrome P450 system, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> interacts with many other medications as a substrate of CYP3A4 and an inhibitor of CYP2C8/9 and 3A4. Some drugs reduce the serum cyclosporine levels, whereas others raise the levels. It is important to check trough cyclosporine levels after any of these medications are added to or withdrawn from the patient's regimen.</p><p></p><p>Observational studies and small placebo-controlled trials have demonstrated the efficacy of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> both in newly treated patients with MG and in prednisone-dependent patients [<a href="#rid28">28-32</a>]. The maximal effect is achieved by seven months on average [<a href="#rid28">28</a>].</p><p>In the largest trial, 39 patients with prednisone-dependent MG were treated with either <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> plus placebo or prednisone plus <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> at a dose of 5 mg/kg per day (in two divided doses) [<a href="#rid30">30</a>]. At six months, the cyclosporine group showed greater improvement in quantitative strength testing. This group also had a nonsignificantly lower mean prednisone dose. Over the subsequent 18 months of open-label follow-up, progressive nephrotoxicity led to discontinuation of cyclosporine in 10 percent, and cumulative side effects led to discontinuation in a total of 35 percent.</p><p class="headingAnchor" id="H16"><span class="h3">Tacrolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> (FK506), most often used after organ transplantation, is an immunosuppressive macrolide molecule similar in action to <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. Like cyclosporine, it has a relatively rapid onset of effect but has a limited first-line role due to the potential for serious toxicities. (See <a class="local">'AChR-positive and seronegative MG'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The dosing of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> is not standardized. In a large observational series in patients with MG, tacrolimus was started at 0.1 mg/kg per day in two divided doses and then adjusted to achieve a plasma tacrolimus drug concentration of 7 to 8 ng/mL [<a href="#rid33">33</a>]. The mean tacrolimus dose was higher at study onset (5.5 mg daily) than at study end (3.5 mg/day). In two randomized trials in patients with MG, a fixed dose of 3 mg daily was used [<a href="#rid34">34,35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">Tacrolimus</a> is less nephrotoxic than <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and this is especially true given its use in MG at doses markedly lower than that used early after organ transplantation. Nephrotoxicity has not been a limiting factor in the experience of treating MG to date [<a href="#rid33">33-41</a>].</p><p></p><p class="bulletIndent1">Side effects of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> include hyperglycemia, hypomagnesemia, tremor, and paresthesias. These generally resolve after adjustment of the dose, if necessary, based on serum levels and magnesium replacement. In one study there was no increase in infections in the tacrolimus group [<a href="#rid41">41</a>]. However, there were three malignancies that developed (two with lung cancer and one with kidney cancer). These all developed within six months of therapy and were felt by the investigators to be unlikely related to the administration of tacrolimus.</p><p></p><p class="bulletIndent1">Although well tolerated in small trials in patients with MG, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> has the potential for severe side effects. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p>Small, randomized trials of <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> have been mixed. In a pilot trial of 34 newly diagnosed patients with generalized MG, patients randomly assigned to low-dose tacrolimus (3 mg/day) required less <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> to maintain minimal manifestations of MG at one year compared with the placebo group, and there were no significant toxicities [<a href="#rid34">34</a>]. In a larger trial of 80 patients with stable MG on prednisolone, the mean prednisolone dose in the last 12 weeks of the study was nonsignificantly lower in the tacrolimus group compared with placebo (4.9 versus 6.5 mg, p = 0.08) [<a href="#rid35">35</a>]. However, the trial was limited by the stable, mildly affected patient population and the short duration (28 weeks) of follow-up.</p><p>In a number of uncontrolled studies, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> has been used successfully to treat MG at low doses (generally 3 to 8 mg/day) with a response rate of 67 to 87 percent [<a href="#rid33">33,37-40</a>]. As an example, one report evaluated 212 patients with MG treated with tacrolimus who were followed for a mean of 49 months [<a href="#rid33">33</a>]. <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">Prednisone</a> was withdrawn in 95 percent of patients. Pharmacologic remission (ie, no symptoms or signs of MG for at least one year while on some form of immunomodulating therapy for MG) or complete remission (ie, no symptoms or signs of MG for at least one year while on no therapy for MG) was achieved by ≥85 percent of patients.</p><p class="headingAnchor" id="H845981469"><span class="h3">Antibody-based biologic therapies</span><span class="headingEndMark"> — </span>Biologic therapies for MG include those that target the Fc-receptor or complement proteins promote autoantibody degradation or inhibit autoimmune-mediated membrane destruction. Onset of effect appears to be faster than several oral agents, making them appealing options for early MG therapy. <a class="drug drug_general" data-topicid="134678" href="/d/drug information/134678.html" rel="external">Efgartigimod alfa</a> was approved by the United States FDA for use in MG in 2021, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> was approved in 2022, and <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a> and <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a> were approved in 2023, but their places in the spectrum of MG treatments have not yet been defined.</p><p class="headingAnchor" id="H2258786174"><span class="h4">Efgartigimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="134678" href="/d/drug information/134678.html" rel="external">Efgartigimod alfa</a> is an IgG antibody Fc-fragment molecule designed to promote degradation of IgG autoantibodies [<a href="#rid42">42,43</a>]. There are several scenarios where efgartigimod may be used. It may be considered early in the course of disease instead of glucocorticoids in diabetic patients or others where glucocorticoids may provide unacceptable risks or have intolerable side effects. It may also be used as a bridge therapy to slower-acting agents (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) or as chronic periodic maintenance therapy. Future data are warranted to assess the long-term effects of efgartigimod and to help identify optimal patients for this therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="134678" href="/d/drug information/134678.html" rel="external">Efgartigimod alfa</a> is given either as a weekly intravenous (IV) infusion at 10 mg/kg or as a subcutaneous formulation (<a class="drug drug_general" data-topicid="141821" href="/d/drug information/141821.html" rel="external">efgartigimod alfa-hyaluronidase</a>) given by a health care provider as a fixed-dose injection [<a href="#rid44">44,45</a>]. The use of the subcutaneous formulation may be preferred in patients with limited venous access. Both formulations are administered by a health care professional and are given weekly for four weeks with observation of the treatment response afterward to determine the next course of treatment. Some patients may have a robust and prolonged response and may only need one or two treatment cycles a year. It may work like maintenance plasmapheresis by reducing antibody levels, without the risks of chronic venous line complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common adverse effects with efgartigimod reported in the phase III clinical trial included headache, nasopharyngitis, and upper respiratory infection [<a href="#rid46">46</a>]. Other adverse effects include leukopenia and development of pathogenic serum antibodies. Adverse reactions reported in postmarketing surveillance include infusion-related reactions such as hypertension, chills, and abdominal pain and hypersensitivity reactions including hypotension and anaphylaxis [<a href="#rid47">47</a>].</p><p></p><p>Efgartigimod was found to be effective in the multicenter ADAPT trial that included 167 patients with generalized MG from North America, Europe, and Japan [<a href="#rid46">46</a>]. Most patients were taking glucocorticoids or other immunosuppressive medications (86 percent), and AChR antibodies were positive in 77 percent. Symptomatic improvement of at least two points in the MG Activities of Daily Living (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmyasthenia.org%2FProfessionals%2FResources-for-Professionals%23%3A%7E%3Atext%3DMG%C2%A0Activities+of+Daily+Living+%28MG-ADL%29&amp;token=pOjjkjpsXVBW901Yqv%2FdEtoRFbC71Cb0%2F%2FAnXhPswr4H3WnstD3OLILtk4Dhmn245vk%2FC3SE%2FNe1IVU5zd7XF2ou69Mjt%2BEDC4Xks4cugyYd%2FR8761XRjayo2DN%2BohCef1s%2FzBNFgCLuADUqj%2B0cmg%3D%3D&amp;TOPIC_ID=5175" target="_blank">MG-ADL</a>) score was more common in patients assigned to weekly infusions of efgartigimod 10 mg/kg IV for four weeks than in those assigned to placebo (68 versus 30 percent). The rate of adverse effects was similar in treatment and placebo groups; headache, nasopharyngitis, and upper respiratory infection were reported most frequently. On the basis of these data, efgartigimod was approved by the FDA and in Japan for use in AchR antibody-positive patients with generalized MG. In a subsequent single-center retrospective review of 17 patients who were treated with efgartigimod, a &gt;50 percent improvement in nonocular symptoms was reported by 16 patients (94 percent) at three-month follow-up [<a href="#rid48">48</a>]. Mean improvements in baseline MG-ADL score were 5.5 and 7.1 points at three and six months, respectively. Most patients were taking glucocorticoids, but only 41 percent had attempted a steroid-sparing agent. Efgartigimod was selected for most patients due to a poor response or contraindication to other therapies.</p><p class="headingAnchor" id="H2765956807"><span class="h4">Rozanolixizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">Rozanolixizumab</a> is a monoclonal antibody that binds to the Fc receptor to promote lysosomal degradation of IgG autoantibodies [<a href="#rid49">49</a>].</p><p>As with other antibody-based biologic agents, there are multiple scenarios where <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a> may be used. It may be considered early in the course of disease instead of glucocorticoids, as a bridge therapy to slower-acting agents, or as chronic periodic maintenance therapy. Rozanolixizumab was approved by the US FDA for patients with AchR-positive or MuSK-positive MG [<a href="#rid50">50</a>]. Future data are warranted to assess the long-term effects of rozanolixizumab and to help identify optimal patients for this therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">Rozanolixizumab</a> is given by a health care provider as a subcutaneous infusion weekly for six weeks according to patient body weight. The dose is 420 mg for patients who weigh &lt;50 kg, 560 mg for patients who weigh 50 to 100 kg, and 840 mg for patients who weigh &gt;100 kg [<a href="#rid50">50</a>]. Subsequent infusion cycles are determined after observation to assess the initial response to treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Common adverse effects with <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a> include headache, infections, and diarrhea.</p><p></p><p>In a placebo-controlled trial of 200 patients with AchR-positive or MuSK-positive MG, improvement in baseline symptoms (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmyasthenia.org%2FProfessionals%2FResources-for-Professionals%23%3A%7E%3Atext%3DMG%C2%A0Activities+of+Daily+Living+%28MG-ADL%29&amp;token=pOjjkjpsXVBW901Yqv%2FdEtoRFbC71Cb0%2F%2FAnXhPswr4H3WnstD3OLILtk4Dhmn245vk%2FC3SE%2FNe1IVU5zd7XF2ou69Mjt%2BEDC4Xks4cugyYd%2FR8761XRjayo2DN%2BohCef1s%2FzBNFgCLuADUqj%2B0cmg%3D%3D&amp;TOPIC_ID=5175" target="_blank">MG-ADL</a> scores) by day 43 was greater among those assigned either to <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a> 7 mg/kg or 10 mg/kg than patients assigned to placebo (least-squares mean difference [-3.37 and -3.4 versus -0.8]) [<a href="#rid51">51</a>]. The mean age of patients was 52 years old, and mean duration since MG diagnosis was 5.8 years; nearly two-thirds of patients were also taking glucocorticoids. Most adverse effects were mild, including headache, diarrhea, fever, and nausea.</p><p class="headingAnchor" id="H4105125958"><span class="h4">Ravulizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">Ravulizumab</a> is a humanized monoclonal antibody that specifically binds with the terminal complement protein C5, preventing disruption of neuromuscular transmission, presumably by inhibiting membrane attack complex-mediated destruction of the postsynaptic membrane. As with efgartigimod, there are several scenarios where ravulizumab may be used. It may be considered early in the course of disease instead of glucocorticoids, as a bridge therapy to slower-acting agents, or as chronic periodic maintenance therapy. Future data are warranted to assess the long-term effects of ravulizumab and to help identify optimal patients for this therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">Ravulizumab</a> is given as by a health care provider as a variable weight-based dose. After a loading dose, the maintenance dose is given two weeks later and then continued every eight weeks thereafter.</p><p></p><p class="bulletIndent1">This medication is structurally similar to <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> but has been altered to maintain a concentration in the serum that requires less frequent dosing at eight-week intervals [<a href="#rid52">52</a>]. Although there are no data in patients with MG, patients with paroxysmal nocturnal hemoglobinuria have been safely and effectively switched from eculizumab administered every two weeks to <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> administered every eight weeks [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – In the phase III clinical trial, there were no treatment-limiting side effects [<a href="#rid52">52</a>]. Headache was the most frequently reported adverse effect and the proportion of patients who experienced adverse effects were similar between groups.</p><p></p><p>Patients should be immunized with meningococcal vaccines at least two weeks prior to administering the first dose of <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>.</p><p>In a trial of 175 patients with MG on glucocorticoids, patients with AchR antibody MG who received <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a> infusions every eight weeks after initial loading doses had greater improvements in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmyasthenia.org%2FProfessionals%2FResources-for-Professionals%23%3A%7E%3Atext%3DMG%C2%A0Activities+of+Daily+Living+%28MG-ADL%29&amp;token=pOjjkjpsXVBW901Yqv%2FdEtoRFbC71Cb0%2F%2FAnXhPswr4H3WnstD3OLILtk4Dhmn245vk%2FC3SE%2FNe1IVU5zd7XF2ou69Mjt%2BEDC4Xks4cugyYd%2FR8761XRjayo2DN%2BohCef1s%2FzBNFgCLuADUqj%2B0cmg%3D%3D&amp;TOPIC_ID=5175" target="_blank">MG-ADL</a> score at 26 weeks than those assigned to placebo (-3.1 versus -1.4) [<a href="#rid52">52</a>]. Patients had mild to moderate symptoms (median MG-ADL score 9), and most were taking glucocorticoids or other immunosuppressants at baseline. The rate of adverse events was similar between groups and the most frequently reported were headache, diarrhea, and nausea. On the basis of these results, ravulizumab was approved by the United States FDA for use in AChR antibody-positive patients with generalized MG.</p><p class="headingAnchor" id="H2529815654"><span class="h4">Zilucoplan</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">Zilucoplan</a> is a macrocyclic peptide that is designed to inhibit cleavage of complement C5 and prevent the development membrane attack complex that contributes to destruction of the postsynaptic membrane.</p><p>The exact role of <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a> in the chronic treatment of MG is uncertain. It may be used as early therapy in place of glucocorticoids, as bridge therapy, or chronic maintenance therapy. Zilucoplan was approved by the United States FDA for use in patients with AChR-positive generalized MG [<a href="#rid54">54</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">Zilucoplan</a> is given as a self-administered daily subcutaneous injection at prespecified doses of 16.6, 23, or 32.4 mg according to actual body weight.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common adverse reactions in clinical trials were injection site bruising, upper respiratory infections, and diarrhea [<a href="#rid55">55,56</a>]. Uncommon serious adverse reactions include meningococcal meningitis and pancreatitis.</p><p></p><p>Patients should be immunized with meningococcal vaccines at least two weeks prior to administering the first dose of <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a>.</p><p>In a clinical trial of 174 patients with generalized MG, improvement in baseline <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmyasthenia.org%2FProfessionals%2FResources-for-Professionals%23%3A%7E%3Atext%3DMG%C2%A0Activities+of+Daily+Living+%28MG-ADL%29&amp;token=pOjjkjpsXVBW901Yqv%2FdEtoRFbC71Cb0%2F%2FAnXhPswr4H3WnstD3OLILtk4Dhmn245vk%2FC3SE%2FNe1IVU5zd7XF2ou69Mjt%2BEDC4Xks4cugyYd%2FR8761XRjayo2DN%2BohCef1s%2FzBNFgCLuADUqj%2B0cmg%3D%3D&amp;TOPIC_ID=5175" target="_blank">MG-ADL</a> scores at 12 weeks was greater among patients assigned to <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a> at a dose of 0.3 mg/kg once daily than those assigned to placebo (least-squares mean difference -2.09, 95% CI -3.24 to -0.95) [<a href="#rid55">55</a>]. Adverse effects were generally mild and included injection site reactions, headache, and diarrhea. Approximately 50 percent of patients were considered treatment refractory at study entry, and more than 60 percent were taking glucocorticoids at baseline.</p><p class="headingAnchor" id="H858318359"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span>Oral <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> may be used as a glucocorticoid-sparing therapy in patients with MG who have not responded to other agents based upon favorable results from an open-label study with a small number of patients [<a href="#rid7">7,57</a>]. However, a 12-month, double-blind, randomized controlled trial of 50 patients with MG found that methotrexate did not significantly reduce the use of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (as measured by the area under the dose-time curve) or improve secondary outcome measures of MG compared with placebo [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H1847896707"><span class="h2">Weaning from glucocorticosteroids</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> and other glucocorticoid-sparing therapies are most commonly started once <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> has been tapered to the lowest dose that will maintain a reasonable clinical response.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering</strong> – After the minimum time to onset of clinical response for the added immunotherapeutic agent has passed (eg, as long as 12 months on <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>), we begin to slowly taper <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> to as low a dose as can be achieved, preferably none at all.</p><p></p><p class="bulletIndent1">Balancing the improvement of MG symptoms with the side effects of the immunotherapies is a constant challenge. Even when steroid-sparing therapies are used, it is common to continue the use of <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a> in order to reduce the required doses of immunotherapeutic drugs in an effort to minimize adverse effects. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Initial symptomatic therapy'</a>.)</p><p></p><p class="bulletIndent1">After the glucocorticoids have been tapered, we then try to taper <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a>. Many, but certainly not all, patients can be minimally symptomatic or in remission on one immunotherapeutic agent alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bridge therapy for patients intolerant to glucocorticoids</strong> – For patients with MG in whom it is especially desirable to avoid glucocorticoids (such as those with poorly controlled diabetes) or for those who are not successfully weaned to lower doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, we often use immunotherapeutic agents with a quicker onset of effect until the more slowly acting immunotherapy takes effect  (<a class="graphic graphic_table graphicRef70721" href="/d/graphic/70721.html" rel="external">table 1</a>). Options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG)</p><p class="bulletIndent2"><span class="glyph">•</span>Plasmapheresis</p><p class="bulletIndent2"><span class="glyph">•</span>Efgartigimod</p><p class="bulletIndent2"><span class="glyph">•</span>Rozanolixizumab</p><p class="bulletIndent2"><span class="glyph">•</span>Ravulizumab</p><p class="bulletIndent2"><span class="glyph">•</span>Zilucoplan</p><p class="bulletIndent2"><span class="glyph">•</span>Eculizumab</p><p></p><p class="bulletIndent1">The most common regimen has been monthly courses of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>. Monthly plasmapheresis is an alternative to IVIG but is frequently limited by venous access problems associated with frequent use [<a href="#rid1">1</a>]. Efgartigimod, <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a>, and <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> may play a similar role in these patients, but experience with these agents in this setting is limited. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Plasma exchange and IVIG as rescue or bridge therapies'</a> and <a class="local">'Antibody-based biologic therapies'</a> above and <a class="local">'Eculizumab'</a> below.)</p><p></p><p class="headingAnchor" id="H2442874626"><span class="h1">REFRACTORY DISEASE</span></p><p class="headingAnchor" id="H3444712778"><span class="h2">Definition and general approach</span><span class="headingEndMark"> — </span>Approximately 10 percent of patients with severe MG are refractory to, or are limited by the specific toxicities of, the first-line glucocorticoid-sparing oral therapies (<a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>) [<a href="#rid59">59,60</a>]. Some require unacceptably high doses of glucocorticoids despite concurrent use of these agents. Refractory disease is generally considered to include patients with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Disease that is unchanged or worse after glucocorticoids and at least one other immunotherapeutic agent, used in adequate dose and duration, with persistent symptoms or side effects that limit function</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for ongoing rescue therapy with intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) or plasma exchange, or frequent myasthenic crises, while on immunotherapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intolerable adverse reactions or the presence of comorbid illnesses that preclude use of conventional immunotherapies</p><p></p><p>There is variability in how the glucocorticoid-sparing therapies are used and ordered among experts. Most would require a minimum of glucocorticoids plus an adequate trial (ie, one year or more) of either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> (but not both), and perhaps efgartigimod, <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, or <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a> before considering a patient to have refractory disease. In such patients, some would also consider a trial of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> before moving on to the treatment options discussed below.</p><p>Although there are no evidence-based guidelines in patients with refractory disease, more aggressive treatment is generally warranted, and the approach is highly individualized [<a href="#rid1">1,7</a>]. <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> may be an effective therapy and has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for this use in refractory acetylcholine receptor (AChR) antibody-positive patients [<a href="#rid7">7</a>]. Chronic, or maintenance, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or plasma exchange (at regular intervals) can be used successfully in patients with refractory generalized MG of any serologic status. Alternative agents include <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid1">1,7</a>]. Rituximab is particularly efficacious in muscle-specific tyrosine kinase (MuSK)-positive MG and should be considered early in the course of the disease. Other biologic therapies may be used for select patients with refractory disease, although experience in this setting is limited.</p><p class="headingAnchor" id="H1041089379"><span class="h2">Pharmacologic options</span></p><p class="headingAnchor" id="H3602041517"><span class="h3">Eculizumab</span><span class="headingEndMark"> — </span>Complement-mediated injury to the postsynaptic membrane likely plays a major role in the pathogenesis of MG. <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> is a humanized monoclonal antibody that binds to C5 and inhibits the formation of C5b-induced membrane attack complex. Based on the available data and considering the potential for infectious complications and lack of comparative and long-term safety and efficacy data, eculizumab is most appropriate to consider in selected refractory patients with severe disease or dependence on maintenance <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or plasma exchange [<a href="#rid7">7</a>].</p><p><a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> was first reported to be of possible benefit in a crossover trial of 14 patients with AChR-positive, refractory MG [<a href="#rid61">61</a>]. A larger multicenter trial of eculizumab (REGAIN) was then performed in 125 patients with generalized AChR-positive MG who had failed at least two immunosuppressive therapies, one of which could have been chronic <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or plasma exchange [<a href="#rid62">62</a>]. Although the trial failed to show a statistically significant difference in the MG Activities of Daily Living (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmyasthenia.org%2FProfessionals%2FResources-for-Professionals%23%3A%7E%3Atext%3DMG%C2%A0Activities+of+Daily+Living+%28MG-ADL%29&amp;token=pOjjkjpsXVBW901Yqv%2FdEtoRFbC71Cb0%2F%2FAnXhPswr4H3WnstD3OLILtk4Dhmn245vk%2FC3SE%2FNe1IVU5zd7XF2ou69Mjt%2BEDC4Xks4cugyYd%2FR8761XRjayo2DN%2BohCef1s%2FzBNFgCLuADUqj%2B0cmg%3D%3D&amp;TOPIC_ID=5175" target="_blank">MG-ADL</a>) total score at 26 weeks (rank-based treatment difference -11.7 points favoring eculizumab, 95% CI -24.4 to 0.96), the majority of other prespecified endpoints favored eculizumab over placebo, including the proportion of patients with ≥5 point improvement in the quantitative MG scale score (45 versus 19 percent) and the rate of MG exacerbations (10 versus 24 percent). On the basis of these data, eculizumab was approved by the FDA and EMA for use in refractory AChR antibody-positive patients. In an open-label extension of the REGAIN trial in which 117 patients were treated with eculizumab 1200 mg every two weeks for up to three years (median 23 months), functional gains were maintained over time, and the exacerbation rate in the open-label extension period was 75 percent lower than the one-year pre-study baseline rate (25 versus 102 events per 100 patient-years) [<a href="#rid63">63</a>]. Other outcomes also supported a sustained benefit, including hospitalization rates and use of rescue therapies. Changes in glucocorticoid dosing and other immunosuppressive therapies were not reported.</p><p><a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> is given by intravenous (IV) infusion starting at least two weeks after vaccination for meningococcal meningitis. The dose in MG consists of 900 mg infused weekly for four weeks, followed by 1200 mg a week later, and then 1200 mg every two weeks. The optimal duration of therapy in responding patients is not yet known. Some experts who have treated patients for longer than six months indicate that they try to lengthen the interval between infusions at a point when the patient appears to have maximally responded. In the REGAIN trial, clinical benefit appeared to occur rapidly in responders, and therefore eculizumab should probably be discontinued if no clinical improvement has occurred by three to four months [<a href="#rid62">62-64</a>].</p><p><a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">Eculizumab</a> increases the risk of life-threatening Neisserial infections, including <em>N. meningitidis</em>, and administration of eculizumab has been associated with a 1000-fold to 2000-fold increased incidence of meningococcal disease. Patients should be immunized with meningococcal vaccines (both quadrivalent ACYW serogroup conjugate and serogroup B) at least two weeks prior to administering the first dose of eculizumab. In addition, daily oral antibiotic prophylaxis should be considered, as described separately, because invasive meningococcal disease has occurred among patients receiving eculizumab despite receipt of meningococcal vaccine [<a href="#rid65">65</a>]. In the United States, eculizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). (See  <a class="medical medical_review" href="/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'</a>.)</p><p>Otherwise, <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a> infusions are generally well tolerated. Commonly reported adverse events in clinical trials include headache (16 to 38 percent), nasopharyngitis (15 to 32 percent), diarrhea (13 to 23 percent), upper respiratory infection, arthralgias, and nausea. Risk of infection, especially with encapsulated bacteria, is increased with eculizumab due to blockade of terminal complement activation. In the REGAIN open-label extension study with a median follow-up of two years, 19 percent of patients developed an infectious event of special interest, including five cases of sepsis, septic shock, or pseudomonas sepsis and one case each of aspergillus, cytomegalovirus, and pseudomonas infection; there was one case of meningococcal infection after the data cutoff that resolved with antibiotics [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H5661854"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is a monoclonal antibody against B cell membrane marker CD20. Originally developed to treat B cell lymphomas, there is a good theoretical rationale for its use in MG, a B cell mediated disease. It has proven to be relatively safe in other autoimmune disorders.</p><p>A large and growing number of case reports and case series support the potential efficacy of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in patients with refractory MG [<a href="#rid66">66-70</a>]. In a prospective study of 22 patients with refractory MG treated with rituximab, the mean time to relapse was 17 months. Among 14 patients taking <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, the mean daily dose decreased from 25 mg at baseline to 7 mg after treatment with a mean follow-up of 29 months [<a href="#rid71">71</a>]. In an observational study of 72 patients with new-onset or refractory generalized MG, those treated with low-dose rituximab had shorter time to remission, lower use of adjunctive treatments, and fewer adverse events than patients treated with conventional immunotherapy [<a href="#rid72">72</a>]. A retrospective study of 40 patients with MG found patients age ≥65 years old improved with rituximab at rates similar to younger patients [<a href="#rid73">73</a>].</p><p>Results of a randomized phase II trial of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> in patients with AChR antibody-positive, generalized MG did not show a significant steroid-sparing effect at one year compared with placebo [<a href="#rid74">74</a>]. However, rituximab may have benefit for some patients with early MG. In a small trial of patients with AChR antibody-positive MG ≤12 months duration, patients assigned to a single dose of rituximab 500 mg had a greater likelihood of minimal manifestations of the disease at 16 weeks and reduced need for rescue medications than those assigned to placebo [<a href="#rid75">75</a>]. Additional data are warranted to assess longer term benefit and help identify patients for early treatment with rituximab.</p><p><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> appears to be particularly effective in patients with MuSK-positive MG, who often respond relatively poorly to first-line immunotherapies [<a href="#rid66">66,76-80</a>]. A 2017 systematic review identified 47 single case reports and cases series totalling 169 patients with MG treated with rituximab, of whom one-third (57 patients) were MuSK positive [<a href="#rid66">66</a>]. Compared with patients with AChR-positive disease, those with MuSK-positive MG were more likely to respond to treatment, with higher rates of minimal disease manifestations or better (72 versus 30 percent) as well as pharmacologic or complete sustained remission for one year or more (47 versus 16 percent). In a multicenter retrospective study that included 77 patients with MuSK-positive MG who were deemed prospectively by blinded reviewers to be reasonable candidates for a trial of rituximab versus placebo within the first year of therapy, the 24 patients who ultimately received rituximab were more likely to have a favorable outcome than the 31 patients who did not receive rituximab (58 versus 16 percent) [<a href="#rid80">80</a>]. Favorable outcome was defined using a novel scale combining postintervention disease status and number and dose of immunotherapies used. The percentage of patients on <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at last follow-up was also lower in patients who received rituximab (29 versus 74 percent).</p><p>The optimal dose and dosing interval of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for MG has not been established. A common initial dose is 375 mg/m<sup>2</sup> weekly for four doses. Others administer 1000 mg as a fixed dose and repeat in two weeks for a total of 2000 mg. Whether and when to repeat rituximab dosing in patients who respond to the initial course is generally guided by clinical symptoms and lymphocyte recovery. Patients who do not respond to the initial regimen can be redosed at six months; such patients who fail to respond to a second course are probably best considered refractory to rituximab [<a href="#rid80">80</a>].</p><p><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is well tolerated by most patients. Both minor and serious infusion reactions may occur, and patients require both premedication and monitoring during and immediately after all infusions. (See  <a class="medical medical_review" href="/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy"</a>.) </p><p>Patients may be more susceptible to certain infections. Rare cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, but it is unknown if rituximab increases the risk of PML [<a href="#rid57">57,58</a>]. (See  <a class="medical medical_review" href="/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1962915454"><span class="h3">Other biologic therapies</span><span class="headingEndMark"> — </span>Other biologic therapies may also be used in patients with refractory MG. Options may include efgartigimod, <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, and <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a>. However, clinical experience with these agents for patients with refractory MG is limited. (See <a class="local">'Antibody-based biologic therapies'</a> above.)</p><p class="headingAnchor" id="H1576013107"><span class="h3">Maintenance IVIG or plasma exchange</span><span class="headingEndMark"> — </span>Periodic administration of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or plasma exchange is sometimes used to maintain remission in patients with MG that is not well controlled despite the use of chronic immunomodulating drugs. There are no studies comparing this strategy with other options for refractory disease, but in the author's experience, maintenance IVIG is necessary and useful in some patients when other strategies have failed. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis", section on 'Plasma exchange and IVIG as rescue or bridge therapies'</a>.) </p><p class="headingAnchor" id="H10254150"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is an alkylating agent that reduces proliferation of both B and T cells. It can be effective in MG, but it has several serious potential side effects. Since there are effective agents with less toxicity, as detailed above, cyclophosphamide is usually reserved for the small percent of cases that are refractory to the other immunotherapies.</p><p>Administration of monthly high-dose IV <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> has demonstrated equally good efficacy and much lower toxicity than daily oral cyclophosphamide in other autoimmune disorders, such as lupus nephritis [<a href="#rid81">81</a>]. Although data are limited, the efficacy of pulsed cyclophosphamide in MG is suggested by the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized, controlled trial of 23 patients with MG who were either poorly controlled or had significant glucocorticoid-related side effects, patients received their usual medications plus IV pulse <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (initial dose 500 mg/m<sup>2</sup> of body surface area) or placebo [<a href="#rid82">82</a>]. Subsequent doses of cyclophosphamide were titrated according to changes in muscle strength and side effects. The dose was not modified as long as clinical improvement occurred and no side effects were observed. However, the subsequent dose was increased by 25 percent of the previous dose if there was no clinical improvement or side effects or increased by 10 percent if the previous dose was higher than 1000 mg/m<sup>2</sup> body surface area. The maximum single dose was 2000 mg/m<sup>2</sup> body surface area. Regardless of muscle strength, the subsequent dose was decreased by 25 percent if there were side effects or if the white blood cell count was &lt;3000/mm<sup>3</sup> or the polymorphonuclear cell count was &lt;2000 mm<sup>3</sup>.<sup> </sup>The cyclophosphamide treatments were given monthly for six months, then every other month, for a total of nine treatments. At one year, the following observations were reported:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was a significant reduction in the mean daily <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose in the treatment group compared with the placebo group (14.4 mg versus 32.5 mg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Five of 12 cyclophosphamide-treated patients were able to get off glucocorticoids altogether, but none were able to do so in the placebo group.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was also a significant increase in muscle strength measures in patients in the treatment arm versus the placebo patients.</p><p></p><p class="bulletIndent1">There were no dropouts in the study due to toxicity of treatment. The incidence of hematologic and infectious complications was the same in both groups. During the study and two subsequent years of follow-up, there were no cases of hemorrhagic cystitis, cardiomyopathy, or pneumonitis. One cyclophosphamide-treated patient developed bladder carcinoma two years after the therapy was administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective report, eight patients with MG refractory to conventional immunotherapy received pulsed IV <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> (750 mg/m<sup>2</sup> every four weeks for six months) followed by oral immunosuppression with a conventional agent [<a href="#rid83">83</a>]. Six patients improved within three months of treatment, while two were nonresponders. At a mean follow-up of 31 months, four patients remained in clinical remission.</p><p></p><p>A novel approach to refractory patients with myasthenia involves the use of high-dose <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> as immunoablative therapy [<a href="#rid84">84,85</a>]. This approach remains investigational.</p><p>The complications of oral daily <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> use are myriad and include anorexia, nausea and vomiting, alopecia, persistent leukopenia, hemorrhagic cystitis, and increased risk of malignancies. As a result, oral daily therapy is seldom used. As noted in the studies above, monthly pulse cyclophosphamide is associated with fewer of these symptoms [<a href="#rid81">81,82</a>]. The risk of late malignancy, including bladder cancer, remains a concern. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>The available immunotherapies for MG are effective. However, their utility is limited by their broad effects on the immune system. Their general immunosuppressive properties also underlie many of their potential serious side effects. Improved understanding of the immune events in MG should allow more focused, immune-based therapies. Experimental immunologic approaches to target T cell signaling pathways, T cell–B cell interactions, B cells, Fc receptors, complement pathways, and proinflammatory cytokines are being considered in MG [<a href="#rid7">7,86-89</a>]. Chimeric antigen receptor T cell therapy (CAR-T) uses autologous lymphocytes combined with the extracellular target antibody domain to enhance T-cell-activated immune response. It is typically used for advanced hematologic cancers. Preliminary data suggest this approach may also have benefit for patients with MG [<a href="#rid90">90</a>]. </p><p>Additional data are warranted to assess the long-term safety and benefit of these agents.</p><p class="headingAnchor" id="H1198966824"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117890.html" rel="external">"Society guideline links: Myasthenia gravis"</a> and  <a class="medical medical_society_guidelines" href="/d/html/122676.html" rel="external">"Society guideline links: Thymomas and thymic carcinomas"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid initial therapy</strong> – For most patients with myasthenia gravis (MG) who remain significantly symptomatic on <a class="drug drug_general" data-topicid="9838" href="/d/drug information/9838.html" rel="external">pyridostigmine</a> or who become symptomatic after a temporary response, we recommend glucocorticoids as initial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Typical dosing</strong> – A typical regimen is oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, started at 20 mg daily, with gradual dose escalation by 5 mg every three to five days to a usual target dose of 60 mg per day (or 1 mg/kg per day, maximum 80 mg daily). Gradual dose escalation is advised to avoid the early transient worsening associated with high-dose glucocorticoids. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent tapering</strong> – To reach the lowest dose necessary to maintain disease stability, glucocorticoids should be gradually tapered approximately one month after an effective clinical response has been achieved. We typically reduce <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> by 5 to 10 mg per month until a daily dose of 30 mg is reached then even more slowly (eg, no more than 5 mg per month). (See <a class="local">'Approach to tapering'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring</strong> – Patients should be monitored regularly for side effects and toxicities of glucocorticoids. Calcium and vitamin D supplementation should be used to reduce bone mineral loss, and <em>Pneumocystis</em> pneumonia prophylaxis should be considered in patients on prolonged courses of steroids, particularly at doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> ≥20 mg daily and other risk factors for immunosuppression. (See <a class="local">'Side effects and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-sparing therapy</strong> – For patients with an insufficient response to glucocorticoids, inability to taper steroids below a reasonably acceptable level without return of symptoms, or intolerance of chronic steroids, we recommend the addition of steroid-sparing immunotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Our preferred first-line agents vary based on individual patient and disease factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with AChR-positive or seronegative MG</strong> – For most patients with acetylcholine receptor (AChR) antibody-positive or seronegative MG, we suggest either <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil as initial steroid-sparing therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative options include <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, efgartigimod, <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a>, <a class="drug drug_general" data-topicid="119990" href="/d/drug information/119990.html" rel="external">ravulizumab</a>, or <a class="drug drug_general" data-topicid="143109" href="/d/drug information/143109.html" rel="external">zilucoplan</a>. (See <a class="local">'AChR-positive and seronegative MG'</a> above and <a class="local">'Administration of specific drugs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with MuSK-positive MG</strong> – For most patients with muscle-specific tyrosine kinase (MuSK)-positive MG, we suggest <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> first line (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). If cost or access to rituximab is prohibitive, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, or <a class="drug drug_general" data-topicid="141867" href="/d/drug information/141867.html" rel="external">rozanolixizumab</a> remain reasonable to use as first-line steroid-sparing therapies. (See <a class="local">'MuSK-positive MG'</a> above and <a class="local">'Rituximab'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Weaning from glucocorticoids</strong> – A slow <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> taper is typically started once the minimum time to onset of clinical response of the steroid-sparing agent has passed. The clinical benefit of immunotherapy may be delayed for 6 to 12 months, with a maximal effect often not seen until one to two years of treatment, depending on agent used  (<a class="graphic graphic_table graphicRef70721" href="/d/graphic/70721.html" rel="external">table 1</a>). (See <a class="local">'Administration of specific drugs'</a> above and <a class="local">'Weaning from glucocorticosteroids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for refractory disease</strong> – Approximately 10 percent of patients with severe MG are refractory to, or are limited by the specific toxicities of, the first-line immunotherapies. In these refractory patients, treatment options include antibody-based biologic therapies, maintenance <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> or plasma exchange, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. (See <a class="local">'Definition and general approach'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016; 87:419.</a></li><li><a class="nounderline abstract_t">Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; :CD002828.</a></li><li><a class="nounderline abstract_t">Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976; 26:729.</a></li><li><a class="nounderline abstract_t">Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15:291.</a></li><li><a class="nounderline abstract_t">Miller RG, Milner-Brown HS, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 1986; 36:729.</a></li><li><a class="nounderline abstract_t">Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974; 290:81.</a></li><li><a class="nounderline abstract_t">Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021; 96:114.</a></li><li><a class="nounderline abstract_t">Evoli A, Batocchi AP, Minisci C, et al. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000; 48:1442.</a></li><li><a class="nounderline abstract_t">Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387.</a></li><li><a class="nounderline abstract_t">Witte AS, Cornblath DR, Schatz NJ, Lisak RP. Monitoring azathioprine therapy in myasthenia gravis. Neurology 1986; 36:1533.</a></li><li><a class="nounderline abstract_t">Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? Ann Neurol 2000; 47:682.</a></li><li><a class="nounderline abstract_t">Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol 2004; 24:41.</a></li><li><a class="nounderline abstract_t">Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis. Ann N Y Acad Sci 1987; 505:589.</a></li><li><a class="nounderline abstract_t">Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci 1981; 377:691.</a></li><li><a class="nounderline abstract_t">Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235:449.</a></li><li><a class="nounderline abstract_t">Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998; 50:1778.</a></li><li><a class="nounderline abstract_t">Hood KA, Zarembski DG. Mycophenolate mofetil: a unique immunosuppressive agent. Am J Health Syst Pharm 1997; 54:285.</a></li><li><a class="nounderline abstract_t">Haberal M, Karakayali H, Emiroğlu R, et al. Malignant tumors after renal transplantation. Artif Organs 2002; 26:778.</a></li><li><a class="nounderline abstract_t">Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005; 65:639.</a></li><li><a class="nounderline abstract_t">Dubal DB, Mueller S, Ruben BS, et al. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis. Muscle Nerve 2009; 39:849.</a></li><li><a class="nounderline abstract_t">Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71:400.</a></li><li><a class="nounderline abstract_t">Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71:394.</a></li><li><a class="nounderline abstract_t">Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci 2003; 998:494.</a></li><li><a class="nounderline abstract_t">Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41:593.</a></li><li><a class="nounderline abstract_t">Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56:94.</a></li><li><a class="nounderline abstract_t">Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56:97.</a></li><li><a class="nounderline abstract_t">Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61:1438.</a></li><li><a class="nounderline abstract_t">Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55:448.</a></li><li><a class="nounderline abstract_t">Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316:719.</a></li><li><a class="nounderline abstract_t">Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681:539.</a></li><li><a class="nounderline abstract_t">Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; :CD005224.</a></li><li><a class="nounderline abstract_t">Lavrnic D, Vujic A, Rakocevic-Stojanovic V, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 2005; 111:247.</a></li><li><a class="nounderline abstract_t">Ponseti JM, Gamez J, Azem J, et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci 2008; 1132:254.</a></li><li><a class="nounderline abstract_t">Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study. Eur Neurol 2005; 53:146.</a></li><li><a class="nounderline abstract_t">Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82:970.</a></li><li><a class="nounderline abstract_t">de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333.</a></li><li><a class="nounderline abstract_t">Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002; 25:111.</a></li><li><a class="nounderline abstract_t">Yoshikawa H, Mabuchi K, Yasukawa Y, et al. Low-dose tacrolimus for intractable myasthenia gravis. J Clin Neurosci 2002; 9:627.</a></li><li><a class="nounderline abstract_t">Konishi T, Yoshiyama Y, Takamori M, et al. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003; 28:570.</a></li><li><a class="nounderline abstract_t">Konishi T, Yoshiyama Y, Takamori M, Saida T. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005; 76:448.</a></li><li><a class="nounderline abstract_t">Ponseti JM, Azem J, Fort JM, et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005; 64:1641.</a></li><li><a class="nounderline abstract_t">Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 2018; 128:4372.</a></li><li><a class="nounderline abstract_t">Guidon AC, Juel VC. Efgartigimod: A novel antibody depletion therapy in myasthenia gravis. Neurology 2019; 92:1079.</a></li><li class="breakAll">VYVGART (efgartigimod alfa-fcab) injection, for intravenous use. US Food and Drug Administration (FDA) approved product information. Revised December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761195s000lbl.pdf (Accessed on June 22, 2023).</li><li class="breakAll">VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc). US Food and Drug Administration (FDA) approved product information. Revised June 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761304s000lbl.pdf (Accessed on June 22, 2023).</li><li><a class="nounderline abstract_t">Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2021; 20:526.</a></li><li class="breakAll">FDA informational package insert for VYVGART® (efgartigimod alfa-fcab) injection. US Food and Drug Administration, 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761195s003lbl.pdf (Accessed on December 15, 2023).</li><li><a class="nounderline abstract_t">Singer M, Khella S, Bird S, et al. Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events. Muscle Nerve 2024; 69:87.</a></li><li><a class="nounderline abstract_t">Smith B, Kiessling A, Lledo-Garcia R, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 2018; 10:1111.</a></li><li class="breakAll">RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use. US Food and Drug Administration (FDA) approved product information. Revised June 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf (Accessed on July 06, 2023).</li><li><a class="nounderline abstract_t">Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 2023; 22:383.</a></li><li><a class="nounderline abstract_t">Vu T, Meisel A, Mantegazza R, et. al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. New England Journal of Medicine Evidence 2022; 1.</a></li><li><a class="nounderline abstract_t">Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 2019; 133:540.</a></li><li class="breakAll">Prescribing and usage information for ZILBRYSQ zilucoplan injections. US Food and Drug Administration, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf (Accessed on October 19, 2023).</li><li><a class="nounderline abstract_t">Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 2023; 22:395.</a></li><li><a class="nounderline abstract_t">Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol 2020; 77:582.</a></li><li><a class="nounderline abstract_t">Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11:97.</a></li><li><a class="nounderline abstract_t">Pasnoor M, He J, Herbelin L, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 2016; 87:57.</a></li><li><a class="nounderline abstract_t">Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 2014; 15:167.</a></li><li><a class="nounderline abstract_t">Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 2018; 11:1756285617749134.</a></li><li><a class="nounderline abstract_t">Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48:76.</a></li><li><a class="nounderline abstract_t">Howard JF Jr, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017; 16:976.</a></li><li><a class="nounderline abstract_t">Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 2019; 60:14.</a></li><li><a class="nounderline abstract_t">Edmundson C, Guidon AC. Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis. Muscle Nerve 2019; 60:7.</a></li><li><a class="nounderline abstract_t">McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep 2017; 66:734.</a></li><li><a class="nounderline abstract_t">Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle Nerve 2017; 56:185.</a></li><li><a class="nounderline abstract_t">Stieglbauer K, Pichler R, Topakian R. 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential. J Neurol Sci 2017; 375:241.</a></li><li><a class="nounderline abstract_t">Iorio R, Damato V, Alboini PE, Evoli A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 2015; 262:1115.</a></li><li><a class="nounderline abstract_t">Lu J, Zhong H, Jing S, et al. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis. Muscle Nerve 2020; 61:311.</a></li><li><a class="nounderline abstract_t">Di Stefano V, Lupica A, Rispoli MG, et al. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry 2020; 91:392.</a></li><li><a class="nounderline abstract_t">Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: Extended prospective study results. Muscle Nerve 2018; 58:452.</a></li><li><a class="nounderline abstract_t">Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol 2020; 77:974.</a></li><li><a class="nounderline abstract_t">Doughty CT, Suh J, David WS, et al. Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old. Muscle Nerve 2021; 64:651.</a></li><li><a class="nounderline abstract_t">Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology 2022; 98:e376.</a></li><li><a class="nounderline abstract_t">Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol 2022; 79:1105.</a></li><li><a class="nounderline abstract_t">Stein B, Bird SJ. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J Clin Neuromuscul Dis 2011; 12:163.</a></li><li><a class="nounderline abstract_t">Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78:189.</a></li><li><a class="nounderline abstract_t">Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 2008; 201-202:90.</a></li><li><a class="nounderline abstract_t">Morren J, Li Y. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review. Muscle Nerve 2018; 58:344.</a></li><li><a class="nounderline abstract_t">Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 2017; 89:1069.</a></li><li><a class="nounderline abstract_t">McCune WJ, Golbus J, Zeldes W, et al. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318:1423.</a></li><li><a class="nounderline abstract_t">De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26:31.</a></li><li><a class="nounderline abstract_t">Buzzard KA, Meyer NJ, Hardy TA, et al. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve 2015; 52:204.</a></li><li><a class="nounderline abstract_t">Drachman DB, Adams RN, Hu R, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci 2008; 1132:305.</a></li><li><a class="nounderline abstract_t">Lewis RA, Lisak RP. "Rebooting" the immune system with cyclophosphamide: taking risks for a "cure"? Ann Neurol 2003; 53:7.</a></li><li><a class="nounderline abstract_t">Guptill JT, Soni M, Meriggioli MN. Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics 2016; 13:118.</a></li><li><a class="nounderline abstract_t">Mantegazza R, Bernasconi P, Cavalcante P. Myasthenia gravis: from autoantibodies to therapy. Curr Opin Neurol 2018; 31:517.</a></li><li><a class="nounderline abstract_t">Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 2019; 15:113.</a></li><li><a class="nounderline abstract_t">Rodolico C, Nicocia G, Damato V, et al. Benefit and danger from immunotherapy in myasthenia gravis. Neurol Sci 2021; 42:1367.</a></li><li><a class="nounderline abstract_t">Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol 2023; 22:578.</a></li></ol></div><div id="topicVersionRevision">Topic 5175 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27358333" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International consensus guidance for management of myasthenia gravis: Executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846640" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Corticosteroids for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/821005" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-term administration of corticosteroids in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6721451" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3703276" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prednisone-induced worsening of neuromuscular function in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4808454" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33144515" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083321" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical characteristics and prognosis of myasthenia gravis in older people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270794" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3762975" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Monitoring azathioprine therapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10805346" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229791" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Management of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3479940" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6951493" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of immunosuppressive drugs (azathioprine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3062134" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633727" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9028422" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mycophenolate mofetil: a unique immunosuppressive agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12197933" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Malignant tumors after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116136" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19358236" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434638" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434639" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14592919" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20405499" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148242" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11148243" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638974" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10932288" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Retrospective analysis of the use of cyclosporine in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547126" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8357194" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A clinical therapeutic trial of cyclosporine in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943844" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immunosuppressive agents for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15740576" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cyclosporine in the treatment of myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096852" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tacrolimus for myasthenia gravis: a clinical study of 212 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900097" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784757" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676738" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11754194" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Successful treatment of myasthenia gravis with tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604270" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Low-dose tacrolimus for intractable myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571458" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical study of FK506 in patients with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716549" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15883336" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30040076" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31118243" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31118243" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31118243" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146511" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34146511" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37990374" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Single institution experience with efgartigimod in patients with myasthenia gravis: Patient selection, dosing schedules, treatment response, and adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130439" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130439" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37059507" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Terminal complement inhibitor ravulizumab in generalized myasthenia gravis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30510079" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30510079" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37059508" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065623" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21819556" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27306628" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24872217" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment-refractory myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29403543" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512355" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29066163" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30767274" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31074870" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28704351" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28164324" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rituximab treatment of myasthenia gravis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28320139" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : 10-year-outcomes after rituximab for myasthenia gravis: Efficacy, safety, costs of inhospital care, and impact on childbearing potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308632" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31875994" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32098874" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rituximab in AChR subtype of myasthenia gravis: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29742795" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Rituximab in refractory myasthenia gravis: Extended prospective study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32364568" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34378210" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients≥65 years old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34857535" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36121672" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21321497" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22218276" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-lasting treatment effect of rituximab in MuSK myasthenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18653247" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461627" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801338" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259286" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115946" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25487528" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18567882" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509842" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : "Rebooting" the immune system with cyclophosphamide: taking risks for a "cure"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26510558" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30156572" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Myasthenia gravis: from autoantibodies to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573759" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Immunotherapy in myasthenia gravis in the era of biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33543421" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Benefit and danger from immunotherapy in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37353278" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
